This study is designed to determine the efficacy and safety of durvalumab in combination with paclitaxel and multiple, novel oncology therapies and durvalumab with paclitaxel alone for the treatment of first-line, metastatic triple-negative breast cancer. Call us anytime. Outpatient Care Centers.
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website. A breast cancer cell photographed by a scanning electron microscope.
Biothera Pharmaceuticals, Inc. Imprime PGG is an innate immune trigger that activates anti-cancer T cells. Durvalumab is a human monocolonal antibody that blocks the immune checkpoint protein, programmed death-ligand PD-L1and allows activated T cells to attack tumor cells.
Study record managers: refer to the Data Element Definitions if submitting registration or results information. Additional patients may be enrolled in order to have 20 evaluable i. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below.
Each listing contains a brief description of the indication for use. Click on the drug name for a complete product profile, including general information, clinical trial results, side effects and manufacture information. Arimidex anastrozole.
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases. To gain full access to the content and functionality of the AdisInsight database try one of the following. If you are a subscriber to this content then contact us at AsktheExpert.
History of Changes: ClinicalTrials. Inclusion Criteria: 1. Provision of informed consent prior to any study specific procedures.
For the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA -mutated g BRCA m or s BRCA m advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. For the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy. For the treatment of adult patients with deleterious or suspected deleterious germline BRCA -mutated g BRCA m advanced ovarian cancer who have been treated with 3 or more prior lines of chemotherapy.